C
ompressive injury of the spinal roots or the dorsal root ganglia and damage to peripheral nerves can induce chronic peripheral nerve pain. Such pain is often persistent and is poorly treated by existing therapies.
From the
Compressive radiculopathy (CR) is the most common cause of disability in Americans younger than 45 years. 1 Each year, 3% to 4% of the US population is temporarily disabled, and 1% of the working-age population is completely and permanently disabled from this condition. 2 CR has been cited as the second most frequent reason to visit a physician for a chronic condition, 1, 3 the fifth most common cause for hospitalization, [4] [5] [6] and the third most frequent reason for a surgical procedure. 2 Hence, the socioeconomic impact of CR is significant.
Currently, the treatment regimen for patients with CR varies between orally administered nonsteroidal antiinflammatory drugs (NSAIDs), analgesics, antidepressants, muscle spasmolytics, physiotherapy, epidural injections, and surgery. [7] [8] [9] [10] [11] [12] Most of these treatments target the acute phase of the injury and may have serious systemic side effects or questionable long-term benefits. In particular, epidural steroid injections are a widely used treatment option in this condition. However, a recent pivotal double-blind, randomized, placebo-controlled, multisite study of patients with central spinal stenosis and moderate-to-severe leg pain demonstrated that while epidural steroid injection may significantly improve leg pain 3 weeks after injection, there is no sustained benefit as compared with control at 6 weeks after injection. 13 It is evident that an effective sustained injection-based therapy for chronic CR pain is lacking.
Poly(ethylene glycol) (PEG) hydrogels have been used for medical applications because of their biocompatible, inert nature. Tremendous progress has been made on the development of novel chemistries for the formation of PEG-based hydrogels with highly tailorable material properties for the controlled release of molecules. 14, 15 However, the phenomenon of biomaterial swelling has severely limited the adoption of hydrogels for use in confined anatomical locations such as those in the central and peripheral nervous systems. The hydrogel described herein was developed to demonstrate nonswelling (syneresis) behavior, which is uncharacteristic of this class of materials and makes this device an attractive drug delivery matrix for use in treating chronic CR. The objective of our study was to assess the effectiveness of our hydrogel to locally release methylprednisolone in a regulated and sustained way at the site of nerve compression. We hypothesize that using our hydrogel as carrier is a superior alternative to the use of steroids alone in a preclinical rat model of compression nerve pain.
MATERIALS AND METHODS

Hydrogel Fabrication Procedure
The drug-loaded hydrogel was comprised of poly(ethylene glycol) diacrylate (PEGDA575) (M n ¼ 575 g mol À1 , SigmaAldrich, St. Louis, MO, USA), ethoxylated trimethylolpropane tri(3-mercaptopropionate) (ETTMP) (M n ¼ 1300 g mol À1 , Bruno Bock Thiochemicals, Marschacht, Germany), and 6a-methylprednisolone 21-hemisuccinate sodium salt (MPSS) (Sigma-Aldrich, St. Louis, MO, USA). The method of gel fabrication was similar to previous reports. 16 In summary, MPSS was dissolved in sterile PBS (pH 7.4) at a known concentration and added to PEGDA575. The resulting PEGDA575 solution was added to 40 wt% solution of ETTMP in PBS in stoichiometric equivalence relative to acrylate and thiol groups. All solutions were passed through a sterile 0.2-mm cellulose or Teflon filter prior to use. The final gel contained 27.5% (w/w) polymer and 2 mg mL À1 MPSS. Hydrogels, both with and without MPSS, were characterized by rotational rheology using an Ares G2 straincontrolled rheometer (TA Instruments, New Castle, DE, USA). Gelation time and final elastic modulus (G 0 ) were measured by dynamic time sweep rheology experiments operating in the linear viscoelastic region (strain ¼ 5%, frequency ¼ 10 rad s À1 ) at 378C.
Animals and Surgical Procedures
All animal use protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the Weis Center for Research, Geisinger Clinic. Male SpragueDawley rats were obtained from Charles River Laboratories and maintained according to the NIH Guide for the Care and Use of Laboratory Animals. Experiments were conducted on adult rats weighing 200 to 220 g. Animals were anesthetized with isoflurane via mask inhalation and the sciatic nerve was exposed at the level of the mid-thigh on the left hindlimb. One tight surgical ligature was tied around the sciatic nerve proximal to the sciatic nerve trifurcation, until a brief twitch was seen in the respective hindlimb. The ligature was left in place for the duration of the study. An oral antibiotic, Clavamox, was administered after surgery in the drinking water (0.48 mg/mL) for each rat for 14 days. Two days postligation, the animals were randomized into four treatment groups. Animals were anesthetized, the initial surgical area was reopened, and 100 mL of the treatment was applied over the top of the ligated nerve. Animals received one of the following: PBS, 2 mg/mL methylprednisolone in PBS, hydrogel alone, or 2 mg/mL methylprednisolone infused in hydrogel.
In Vitro MPSS Release Study
Hydrogels (100 mL, diameter:thickness ¼ 2:1) were fabricated as stated above in the presence of MPSS (2 mg mL À1 , 1, 200 mg total loading). Gels were allowed to cure for 10 minutes at 378C and were subsequently placed in 1 mL of PBS. The study was conducted for 21 days and at predefined time points, all of the PBS was removed and replaced with fresh buffer in attempts to maintain sink conditions. The extracted buffer was then diluted 1:1 in acetonitrile and analyzed for steroid using RP-HPLC (Agilent 1260) equipped with an Atlantis T3 (4.6 mm Â 250 mm, Waters Corporation, Milford, MA, USA) column and a 60:40 (water:acetonitrile) þ 0.1% formic acid isocratic mobile phase. MPSS undergoes hydrolysis and potential rearrangement to form methylprednisolone and methylprednisolone 17-hemisuccinate, respectively. All three compounds were resolved and quantified using the described analytical technique.
In Vitro Hydrogel Degradation and Swelling
Hydrogels were formed (100 mL, diameter:thickness 
Nociceptive Analysis
Mechanical Hyperalgesia was assessed 7, 14, 21, and 28 days after surgical ligation using the Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio, Italy). Animals were placed in a clear plexiglass box with a wire mesh floor over the stimulator unit of the aesthesiometer. After acclimation to the cage, the aesthesiometer filament was applied to the plantar surface of the ipsilateral hind paw with a constant force at 5 grams/s (maximum force of 50 grams) until paw withdrawal. Animals without ligation were also assessed as a control. A repeated measures ANOVA followed by a post hoc Dunnett's test was used to compare differences between ligation with treatment groups to unligated control animals (n ¼ 10 for each group) (Graphpad Prism).
Gait Analysis
Gait analysis was conducted using the Catwalk automated gait analysis platform (Noldus, Leesburg, VA, USA). Animals were placed on a contained glass walkway, which is illuminated with a fluorescent light and video monitored by a camera mounted below the walkway. As pressure is applied to the face of the glass, the print is illuminated and the luminescence in proportional to the intensity of pressure. 17 Animals were trained to use the platform each day for 1-week period before the induction of sciatic nerve injury. Compliant runs were determined by passage through the field of view in 10 seconds, and three compliant runs were collected for each animal. Animals were assessed on Days 4, 11, 18, and 25 after ligation by two independent and blinded observers.
Gait analysis parameters used were Max Contact/Max Intensity, which correlates to mechanical allodynia, 18 Swing Speed, and Sciatic Functional Index. 19 Max Contact/Max Intensity measurements were collected for both hindlimbs and the results were converted to the difference between ipsilateral and contralateral intensity measurements normalized to the contralateral measurement for each animal. Repeated measures ANOVA followed by a post hoc Newman-Keuls test were performed to compare differences over time within treatment groups (Graphpad Prism).
Methods for monocyte chemoattractant protein-1 (MCP-1) expression, immunohistochemistry, and HPLC analysis of systemic steroid concentration are presented in Supplementary data, http://links.lww.com/BRS/B67.
RESULTS
To assess if sustained local release of methylprednisolone sodium succinate (MPSS) from a thiol-acrylate poly(ethylene glycol) hydrogel can alleviate pain associated with chronic CR, we formed an injectable hydrogel using a Michael-type conjugate addition reaction between thiol and acrylate groups in stoichiometric equivalence ( Figure 1A) . 16 The gelation kinetics were studied under physiological conditions (pH 7.4, 378C) using dynamic rheology. Figure 1B demonstrates rapid sol-gel conversion of hydrogels formed with and without MPSS. Gelation crossover time ($G 0 /G 00 ¼ 1) for nondrug loaded and drug-loaded hydrogels was found to be 2.0 AE 0.1 and 2.5 AE 0.2 min, respectively. Both gel formulations reached equivalent final mechanical properties (G 0 $14 kPa), indicating that the therapeutic does not alter the network structure. The kinetics of drug release from the highly crosslinked PEG hydrogels was also studied under simulated physiological conditions. Figure 1C illustrates prolonged release of MPSS up to 10 days in vitro. Because of the small molecular size and hydrophilic nature of MPSS, a significant burst effect was observed in the first 24 hours ($75%). The remaining steroid (25%, 50 mg) was released over the next 9 days (total 10 days) resulting in $100% recovery (200 mg total).
To discover if prolonged release of MPSS in vivo using our hydrogel could have a long-term suppressing effect on the inflammatory reaction and subsequently on the perception of pain in a preclinical rat model of chronic peripheral neuropathic pain, we conducted a 4-week sciatic nerve ligation study in rats. Since every day of the rat life is equivalent to 34.8 human days, 4 weeks of monitoring corresponds to approximately 3 years in humans. 20 We included five groups of adult male Sprague Dawley rats: unligated control (CTL), hydrogel only (H), PBS only (PBS), steroid only (S), and hydrogel þ steroid (HþS). The treatment was directly applied to the exposed sciatic nerve 2 days after injury to correlate with the timing of demyelination and degeneration after sciatic nerve injury 21 ( Figure 2A and B). We also examined if the hydrogel exerts any inflammatory effect on the unligated sciatic nerve. Hematoxylin Eosin (HþE) staining of sciatic nerves without ( Figure 2C ) or with ( Figure 2D ) the addition of hydrogel reveals no detectable difference 1 week after the application of hydrogel to the sciatic nerve. Quantification of mechanical hyperalgesia over a period of 4 weeks, which corresponds to chronic neuropathic lesion, 22 was examined with the Randal Sellito test using a Dynamic Plantar Aesthesiometer. 23 Two blinded observers performed the analysis. We found that chronic sciatic nerve ligation resulted in a significant decrease in pain tolerance (increased hyperalgesia) in animals treated with PBS, H alone, or S alone as compared with unligated animals ( Figure 2E , P < 0.05). However, application of HþS reduced hyperalgesia such that the difference in tolerance of painful mechanical stimuli over the course of 4 weeks was not significantly different between H þ S treated animals and unligated control animals ( Figure 2E ). We employed a repeated measures ANOVA followed by a post hoc Dunnett's test to perform statistical analysis of the differences between ligation with treatment groups to unligated control animals (n ¼ 10 for each group) (P < 0.05).
To explore if treatment with HþS results in systemic release of the steroid through vascular absorption, we measured the levels of MPSS in the circulation. We collected the blood through a vena cava puncture from euthanized rats 1 and 2 weeks after the initial application and used HPLC to quantify the plasma levels of MPSS. These results demonstrated that levels of circulating MPSS in the plasma were undetected after 1 or 2 weeks of treatment with the MPSS-loaded hydrogel (Supplementary Table 1 , http://links.lww.com/BRS/B67).
The extent of gait impairment in our rat radiculopathy model and the effect of our treatment on the gait pattern were assessed using the Catwalk automated gait analysis platform (Noldus, Leesburg, VA, USA). 17 Rats were trained to walk with a continuous pace on the CatWalk corridor daily for 1 week prior to the induction of sciatic nerve injury. During week 1 after sciatic nerve ligation most animals had dramatically reduced use of the ipsilateral hind leg, whereas by week 4, H þ S treated animals exhibited a significant improvement in gait and weight-bearing by the affected paw (representative photomicrographs, Figure 3A , B, Suppl. Movies 1, http://links.lww.com/BRS/B68 and 2, http://links.lww.com/BRS/B69). The paw pressure during each step was measured from the intensity of each footprint (representative trials, Figure 3C , D), and treatment effects were analyzed over the course of 4 weeks by two blinded observers. Both treatments with H þ S, or S alone, resulted in significant improvement in the measurement of maximum intensity/maximum contact produced by the affected paw ( Figure 3E ) as compared with nontreated animals (P < 0.05). H alone also exhibited a temporary, significant improvement at week 2 ( Figure 3E ) as compared with nontreated animals. Animals treated with PBS alone exhibited only a mild improvement in the paw pressure of the affected paw through four weeks of analysis ( Figure 3E ). The statistical analysis of the results was performed with repeated measures ANOVA followed by a post hoc Newman-Keuls test (P < 0.05). Analysis of gait swing speed was also used to assess H þ S treatment after sciatic nerve ligation. Swing speed incorporates the measurements stride length and swing duration. Both treatment groups, H þ S and S alone, exhibited significant improvement in swing speed by week 3 and week 4 postligation ( Figure 3F ) (P < 0.05). H alone and PBS-treated animals showed a slight increase in swing speed over time, but were not significantly improved ( Figure 3F) .
To identify the extent of macrophage infiltration after sciatic nerve ligation we isolated the injured sciatic nerves and stained these tissues with the macrophage marker CD68. 24 We show that HþS treated animals (n ¼ 6) exhibit a significant decrease in the number of infiltrating macrophages 1 week after sciatic nerve injury as compared with the H or S only groups (P < 0.05, Figure 4A and B). We performed our studies 1 week after injury since this time coincides with significant increase in the number of infiltrating macrophages after sciatic nerve injury in rodents. 25 The number of infiltrating CD68þ cells in HþS treated animals is not significantly different from the control unligated nerves. MCP-1 is secreted by macrophages and has been recently implicated in the generation of peripheral neuropathic pain. 26 To determine the levels of MCP-1 in the sciatic nerves, we prepared total protein lysates from uninjured mice and injured mice treated with PBS, H, S, and HþS (n ¼ 2 from each treatment group). We demonstrate significant decrease (P < 0.05) in the levels of MCP-1 expression in HþS treated animals 1 week after the injury as compared with S, H, or PBS treated animals. P value was calculated from five independent experiments using lysates from two animals per group and MCP-1 expression was measured using a MSD Sector multiplex reader (Figure 4C and D) . Our results suggest that sustained local release of MPSS from the hydrogel adequately interferes with the macrophage inflammatory response to reduce the levels of MCP-1.
DISCUSSION
Here, we describe the sustained local release of MPSS from a nonswelling, thiol-acrylate poly(ethylene glycol) hydrogel in a preclinical animal model of chronic neuropathic pain because of complete sciatic nerve ligation. PEG-based hydrogels were utilized as a biocompatible, MPSS-delivery matrix to prolong the steroid action when treating CR. These gels formed rapidly under physiologic conditions in the absence of an external catalyst to form highly crosslinked, nonswelling networks which retard the therapeutic diffusion into the local injured environment. Mass loss and swelling studies confirm that the hydrogel is present throughout the 4-week study and that the swelling ratio remains constant throughout the majority of the gels degradation time ( Figure S1 ). In vitro release experiments demonstrate an initial burst release of 75% of MPSS in the first 24 hours followed by an extended release of the remaining 25% of MPSS up to 10 days. It is important to note that these in vitro experiments were performed under simulated near-sink conditions to demonstrate non-steady-state Fickian diffusion as a critical transport mechanism. However, the sink conditions modeled in vitro do not necessarily recreate the local tissue microenvironment in vivo and it is feasible that local therapeutic accumulation may occur once released from the device that would ultimately contribute to mass transport resistances. 27 This may result in a decreased rate of release (after the initial burst of drug facilitated by hydrogel syneresis) and hence provide the basis for delivery that could be sustained for a longer time period than estimated in vitro. The efficacy data presented in this current work support this suggested deviation from Fickian diffusion conditions. Furthermore, the time course of therapeutic release from hydrogels can be engineered from days to months to treat a variety of medical conditions. Techniques could readily be applied to regulate the duration of release from hydrogels for longer or shorter than the 4-week period studied here 28 even though the 4-week period in rats corresponds to approximately 3 human years. 20 We need to point out, however, that our studies currently pertain exclusively to the preclinical rat model and we do not have evidence to support a comparable prolonged release in humans.
Our animal data show that using the MPSS-loaded hydrogel results in significant decrease in pain sensitivity over the course of 4 weeks as compared with animals treated with a bolus injection of steroid, hydrogel alone, or PBS (P < 0.05). Pain sensitivity quantified as hyperalgesia is an accurate measurement of the perception of pain in response to noxious stimuli in rodent models of CR. 29, 30 In addition, automated gait pattern analysis using the CatWalk system (Noldus, Leesburg, VA, USA) shows that treatment with the MPSS-loaded hydrogel results in significant improvement in the gait of animals with complete ligation of the sciatic nerve over a period of 4 weeks as compared with nontreated Significant decrease in pain threshold compared with control animals is identified by Ã (P < 0.05, two-way ANOVA, Dunnett's multiple comparison). Hydrogel plus steroid-treated animals did not exhibit a pain threshold that was significantly different from control animals from week 1 to week 4. Graph depicts average reduction in pain threshold AE SEM.
animals. Finally, the MPSS-loaded hydrogel results in decrease in mechanical allodynia and increase in the swing speed at the same level as MPSS alone. Mechanical allodynia does not require activation of peripheral nociceptors and refers largely to pain evoked by Ab-fibers or low-threshold Ad-and C-fibers. 29 The MPSS-loaded hydrogel showed similar efficiency in reducing mechanical allodynia to MPSS alone (P < 0.05). This is an important observation since allodynia is a major concern for patients with compressive radiculopathy. Our proposed treatment with hydrogelþste-steroid exhibits equal efficiency to steroids alone toward allodynia and increased efficiency for mechanical hyperalgesia. These two attributes in combination with the ability of our hydrogel to prolong the release of steroids and hence extend the short-term effect of epidural steroid injections make our treatment a potentially superior alternative to steroids alone.
In damaged peripheral nerves, as in many other tissues, macrophages are recruited by chemotactic molecules present in the local microenvironment. Several lines of evidence indicate that macrophages are important in neuropathic and CR pain models. 31 -35 Most of these studies have shown a correlation between the invasion of macrophages in peripheral nerves and the development of allodynia or hyperalgesia. Macrophages secrete chemokines, which mediate the inflammatory tissue response and attract leukocytes to the site of injury. MCP-1 is secreted by macrophages and has been recently implicated in the generation of peripheral neuropathic pain. 26 MCP-1 is not expressed at high levels in the normal nervous system, although its synthesis can be significantly upregulated in response to different types of injury. 36, 37 In our chronic peripheral neuropathic pain animal model, the application of the MPSS-loaded hydrogel resulted in significant decrease in the amount of MCP-1 in the injured sciatic nerve as compared with MPSS alone, which suggests that sustained release of MPSS from the hydrogel interferes with the macrophage inflammatory response to reduce the circulating MCP-1 chemokine and subsequently suppress hyperalgesia.
CR is a chronic disease that affects millions of people and has tremendous socioeconomic impact. Currently, a (E) Measurement of maximum intensity/maximum contact produced by the affected paw shows that both the treatments with H þ S or S alone result in significant improvement (P < 0.05). Hydrogel alone also exhibited a temporary, significant improvement at week 2, but animals treated with PBS alone exhibited only a mild improvement in the paw pressure of the affected paw through 4 weeks of analysis. (F) Both treatment groups, H þ S and S alone, exhibit a significant improvement in swing speed by week 3 and week 4 postligation (P < 0.05). Hydrogel alone and PBS-treated animals showed a slight increase in swing speed over time, but were not significantly improved.
nonsurgical treatment of choice is the epidural bolus steroid injection to temporarily alleviate the acute inflammation in spinal roots and regulate the associated pain. However, this treatment cannot address the chronic nature of the disease and repeated injections of steroid carry potentially serious side effects because of systemic absorption of the steroid. We propose the use of a thiol-acrylate poly(ethylene glycol) hydrogel for the sustained local release of steroid as a superior alternative to bolus steroid injections. Translation of our in vivo results to the clinic could transform the field of chronic neuropathic pain management and improve the quality of life for patients living with disabling pain.
Limitations
There are certain limitations of the current study that need to be addressed prior to clinical translation. In particular, in addition to our current MCP-1 data, we need to perform an excessive assessment of our treatment with hydrogelþsteroid on the expression of inflammatory mediators that contribute to local neuroinflammation and pain. In addition, the in vivo concentration of steroid released by the hydrogel should be quantified over the course of the treatment period. Finally, putative systemic effects because of chronic release of steroid should be reported.
Key Points
CR affects millions worldwide. A sustained treatment for chronic CR does not exist. We show that local and sustained release of methylprednisolone from a biodegradable hydrogel provides significantly better control of pain in an animal model of chronic CR as compared with steroids alone (P < 0.05). Animals treated with hydrogel plus steroid showed significant reduction in the number of infiltrating macrophages at the sciatic nerve (P < 0.05) and reduced expression of the neuroinflammatory chemokine MCP-1.
